Edgewise Therapeutics, INC 8-K filings

Edgewise Therapeutics announced positive Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy and completed a $2.65 billion sale of its sevasemten and muscular dystrophy business, sharpening focus on its cardiovascular pipeline.

Edgewise Therapeutics files an 8-K/A to amend its previous report, providing pro forma financial information following the $1.55 billion sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals.

Edgewise Therapeutics has completed the sale of its sevasemten compound and related assets for its muscular dystrophy program to Servier Pharmaceuticals for up to $2.65 billion, allowing it to focus on its cardiovascular pipeline.

Edgewise Therapeutics stockholders re-elected three directors and ratified the appointment of KPMG LLP as the company's independent auditor.

Edgewise Therapeutics announces the sale of its sevasemten asset and muscular dystrophy business to Servier for up to $2.65 billion, shifting focus to its cardiovascular pipeline.

Edgewise Therapeutics reports Q1 2026 results, highlighting positive long-term data for sevasemten in Becker muscular dystrophy and advancing its HCM and heart failure programs.

Edgewise Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its muscular dystrophy and cardiovascular clinical programs with key data readouts expected in 2026.

Edgewise Therapeutics, Inc. announced the appointment of Christopher Martin, a seasoned commercial biotech executive, to its Board of Directors.

Edgewise Therapeutics announced the appointment of Michael Nofi as Chief Financial Officer, succeeding the retiring R. Michael Carruthers, effective November 10, 2025.

Edgewise Therapeutics reported its third quarter 2025 financial results, highlighting significant progress across its muscular dystrophy and cardiac programs with key clinical trial updates and a strong cash position.

Edgewise Therapeutics announced positive clinical data for its muscular dystrophy and cardiomyopathy programs, alongside a reduced net loss and robust cash position for Q2 2025.

Edgewise Therapeutics announced positive clinical trial results for its sevasemten program in Becker and Duchenne muscular dystrophies, including a clear path to registration for Becker with the FDA.

Edgewise Therapeutics reports positive top-line results from its Phase 2 CIRRUS-HCM trial and a strengthened balance sheet following a $188 million net proceeds public offering.

Edgewise Therapeutics secures $200 million through a direct stock offering to advance its muscle disease and cardiac programs.

Edgewise Therapeutics reports positive top-line data from its Phase 2 CIRRUS-HCM trial, showcasing EDG-7500's potential in treating hypertrophic cardiomyopathy.

Edgewise Therapeutics announces positive results from its Phase 2 CANYON trial and reports its financial results for the fourth quarter and full year 2024, highlighting progress in its muscular dystrophy and cardiovascular programs.

Edgewise Therapeutics has promoted Behrad Derakhshan to Chief Operating Officer, effective immediately, with a corresponding increase in salary and bonus target.

Edgewise Therapeutics' Phase 2 CANYON trial of sevasemten in Becker muscular dystrophy met its primary endpoint, showing a significant reduction in creatine kinase levels.

Edgewise Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical programs, including the upcoming top-line results from the Phase 2 CANYON trial.

Edgewise Therapeutics, Inc. has adopted a new equity incentive plan to attract and retain key personnel, reserving 2,000,000 shares for issuance.

Edgewise Therapeutics reported its second quarter 2024 financial results and provided updates on its clinical programs for EDG-7500 and sevasemten.

Edgewise Therapeutics amended its charter to limit officer liability and elected three Class III directors at its 2024 Annual Meeting of Stockholders.

Edgewise Therapeutics has established a sales agreement with Leerink Partners to potentially sell up to $175 million of its common stock through an at-the-market offering program.

Edgewise Therapeutics reported positive results from multiple clinical trials for their muscle disease programs and announced their first quarter 2024 financial results.

Edgewise Therapeutics has appointed Arlene Morris, a seasoned biotech executive, to its Board of Directors, effective May 6, 2024.

Edgewise Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting advancements in clinical trials for their muscle disease therapeutics and a strengthened financial position following a recent public offering.

Edgewise Therapeutics has secured approximately $240 million through a registered direct offering of common stock, expected to fund operations into 2027.

Edgewise Therapeutics reports preliminary year-end financials, including $318.4 million in cash, and outlines key clinical trial milestones for 2024.